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Summary Amplification of the CCDNI gene encoding cyclin DI was examined by Southern blotting and
multiplex polymerase chain reaction (PCR) and occurred in 8 of 53 patients (15%) with primary resected non-
small-cell lung cancer (NSCLC). These tumours and 17 additional tumours with a normal gene copy number
showed overexpression of cyclin Dl (25/53, 47%), as assessed by immunostaining using a monoclonal
antibody. In 22/25 cases, cyclin DI was localised in the cytoplasm, but some (7/25) had simultaneous nuclear
staining. This result is in marked contrast to that reported in breast, hepatocellular and colorectal carcinoma
studies where immunostaining was invariably nuclear. Examination of a restriction fragment length
polymorphic (RFLP) site within the 3'untranslated region of the cDNA following reverse transcriptase
(RT)-PCR (29/53 informative cases) showed a strong association between cytoplasmic staining and imbalance
in allele-specific message levels. Cyclin Dl overexpression was associated with a poorly differentiated histology
(P=0.04), less lymphocytic infiltration of the tumour (P=0.02) and a reduction in local relapse rate (P=0.01).
The relative risk of local relapse was 9.1 in tumours without cyclin Dl overexpression (P=0.01, Cox regression
analysis). We conclude that genetic alteration of cyclin Dl is a key abnormality in lung carcinogenesis and may
have diagnostic and prognostic importance in the treatment of resectable NSCLC.
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Advances in molecular biology paved the way for the
identification of proteins responsible for the regulation of
cell proliferation. One of these molecules, cyclin Dl, is
expressed during the early phase of the cell cycle, before the
restriction point (START), beyond which cells are committed
to enter S phase. This cyclin may act as an initiator ofthe cell
cycle, and perhaps as a growth factor sensor (Xiong et al.,
1991; Motokura and Arnold, 1993a,b; Sherr, 1993; Hunter
and Pires, 1994; Marx, 1994). The ability of cyclin Dl to
immortalise cells in vitro established its oncogenic activity
(Hinds et al., 1994; Lovec et al., 1994). The cyclin Dl gene
(CCNDI) is one of the most frequently amplified chromoso-
mal regions (11q13) in human carcinomas (Motokura and
Arnold, 1993b). In laryngeal (Jares et al., 1994) and head and
neck carcinomas (Muller et al., 1994; Michalides et al., 1995),
its overexpression has been shown to be associated with
advanced local invasion and presence of lymph node
metastases. Cyclin Dl may therefore play a key role in cell
growth regulation and tumorigenesis.
Lung cancer is a worldwide problem and in many
countries it is the most lethal malignancy. As relapse is
frequent after resection of early stage non-small-cell lung
cancer (NSCLC) (Ginsberg et al., 1993), there is an urgent
need to define prognostic factors. These would help in the
choice of the best therapeutic procedure (wide surgical
resection, (neo-)adjuvant chemo- and/or radiotherapy). In
this study we will provide evidence that, surprisingly, cyclin
DI overexpression is associated with lower local relapse risk
in resectable NSCLC, despite also being associated with poor
tumour differentiation, known to be a negative indicator.
Patients and methods
Patients' characteristics and tumour specimens
Tumour samples were obtained from 53 consecutive patients
[49 men, four women, median age 64 years (45-79)] who
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underwent resection of staged resectable NSCLC at the
University Hospital of Berne, Switzerland. They had received
no therapy before surgery [pneumonectomy (n= 15) or
lobectomy (n=38)]. Twenty-nine patients were in stage 1,
five in stage 2 and 19 in stage 3 (UICC, 1987). All tumours
were classified according to the standard criteria of the WHO
(1981), by two pathologists, independently (HJA, PSH): there
were 35 squamous carcinomas, 11 adenocarcinomas, four
undifferentiated NSCLC, two large-cell carcinomas and one
carcinoid. Tumour size was measured by the pathologists on
the fresh specimen. The lymphocytic infiltration of the
tumour, the amount of necrosis and vascular infiltration
were determined histologically. Thirty-three of 53 patients are
alive with a median follow-up of 16 months (range 2-42). In
order to examine the possibility whether the immunostaining
result was due to fixation artifacts we analysed also 33
NSCLC tumour sections prepared in the Wythenshawe
Hospital for cyclin Dl overexpression.
DNA and RNA extraction
DNA and RNA were isolated from frozen tissue samples.
High molecular weight DNA was prepared according to
standard protocols (Blin et al., 1976) and RNA was extracted
using Dynabeads (Dynal, Oslo, Norway) (Jakobsen et al.,
1990) before being reverse transcribed to cDNA (Superscript
Preamplification System, Life Technologies, Paisley, UK).
Southern blot analysis
TaqI digests of 5,g of genomic DNA were blotted onto
Hybond-N filter (Amersham, Buckinghamshire, England).
Purified DNA probes (CCNDJ, nt: 1100- 1888 and adenosine
deaminase, ADA, assigned to chromosome 20q12- 13, nt:
34275-34785) were labelled with _-32P-dCTP (Amersham)
using a random-primed DNA labelling kit (Boehringer,
Mannheim, Germany) and hybridised overnight to the
immobilised DNA. Filters were subsequently washed for
30 min, once with 2 x SSC and once with 0.5 x SSC at 65°C
and exposed to Kodak X-OMAT film at -70°C for several
days. The CCNDI gene was considered amplified when theCyclin DI in non-small-cell lung cancer
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intensity of the ratio CCNDI/ADA signal (assessed by
Phosphor Imager analysis, 425S, Molecular Dynamics) was
increased at least 3-fold relative to the ADA gene signal,
which served as an internal control for DNA loading and
which was assumed not to be amplified in lung tumours.
Digested DNA isolated from normal lung tissue from each
patient was used as a control.
PCR
The PCR multiplex was performed as described (Edwards and
Gibbs, 1994). The CCNDI gene (chromosome 1Iq13) was
compared with the adenosine deaminase (ADA) gene
(chromosome 20ql2- 13) and the progesterone receptor (PR)
gene (chromosome 1 1q23). The following primers were used:
CCNDI: 5'ATATTCCGTAGGTAGATGTGTAAC 3',
5'TGTCACTATTTCGTCTTCTC 3'; ADA: 5'GCGGGTG-
AACGTCAATGTGTTC 3', 5'CAACCTGAAGAGAGT-
GTGCAAG 3'; PR; 5'GGTTTGTTTCTCACTCATATAGC
3', 5'GTAGGACCTCAAGGTGTAGC 3'. Genomic DNA
(2gg) was added to 98 M1 of a PCR mixture containing dNTP
at 250 gM, 0.5 ig of each CCNDI and 0.05 Mg ADA primers
or 0.17 jg PR primers (the ADA and PR primer concentra-
tions were reduced in order to obtain an equal amplification
compared with CCNDI in normal lung tissue), 1 x PCR buffer
(Boehringer) and 2 U Taq polymerase (Boehringer). PCR
cycles (30) were run in an automated thermocycler:
denaturation 94°C, 1 min, annealing 57°C, 1 min, and
elongation temperature 74°C, 1 min. PCR products were
visualised on 2% agarose gels. For the RFLP analysis of the
3'UTR of the cyclin Dl genomic and cDNA the following
primers were used: primary PCR (30 cycles), only for cDNA:
5'ACAACTTCCTGTCCTACTACCG3', 5'ATAGTAGCG-
TATCGTAGGAGTG 3' and secondary PCR (genomic
primary, 30 cycles) cDNA analyses (1 il of a 1:100 dilution
of primary PCR amplification, 28 cycles) 5'-CTCTTGGTTA-
CAGTAGCGTAGC3', 5'-ATCGTAGG-AGTGGGACAG-
GT-3'. The PCR products were digested with the restriction
enzyme HaeIII and visualised on 2% gels. Allelic imbalance in
DNA/cDNA derived products was determined visually with
reference to normal control DNA samples.
Statistical analyses
Patients were placed into two groups according to their cyclin
DI expression. Associations of group membership with other
patient and tumour characteristics were made with chi-square
tests for categorical features and Mann-Whitney U-tests for
continuous ones. Disease end points analysed were overall
survival and event-free survival (EFS) (defined as the time to
the first of: (i) local relapse with or without metastases; (ii)
metastases alone; (iii) death from an unrelated cause).
Kaplan-Meier survivor function estimates were used and
simple comparisons between the two groups were made with
the log-rank test. EFS is a mixing of three types of event
(Kay et al., 1983) and the type-specific cumulative event rates
were estimated with the Nelson estimator (Nelson, 1969).
Cox regression (Cox, 1972) was used to investigate if the
group difference with respect to the local relapse rate
remained after adjustment for age, T-stage, N-stage and
tumour differentiation.
Results
Amplification of the CCND1 gene in NSCLC
Fifty-three patients with operable NSCLC were investigated
for CCNDI gene amplification by Southern blotting and
multiplex PCR analyses. In 8/53 (15%) of the NSCLC a 3- to
20-fold amplification of the CCNDI gene was identified (5/35
squamous cell, 2/11 adeno- and 1/2 large cell carcinoma,
Figure 1). This result was confirmed by a PCR multiplex
comparing CCNDI amplification with the amplification of
the adenosine deaminase gene (chromosome 20ql2-13), and
numerical differences in chromosome 11 copy number were
excluded by a PCR multiplex, comparing CCNDI with the
progesterone receptor gene located on the same arm of
chromosome 11 (Figure 1). Five patients with amplification
were informative for the cyclin DI gene polymorphism
(Heighway, 1991); allelic imbalance was observed in each
case supporting the amplification data obtained by Southern
blotting and PCR multiplex.
Immunohistochemistry
The immunohistochemistry was performed as described
previously (Gillett et al., 1994). Briefly, formalin-fixed paraffin
sections (4 ,uM) from the 53 primary lung tumours prepared in
Berne, 33 in Manchester and 14 breast cancers were airdried on
2% 3-aminopropyltriethoxysilane (APTS) (Sigma, Poole, UK)-
coated slides. After dewaxing in xylene, the sections were
treated for 15 min with 300 ml methanol and 10 ml hydrogen
peroxide in order to block endogenous peroxidase and rinsed
thoroughly in water. They were then placed in citrate buffer,
boiled twice in a microwave, washed with water and placed in
TRIS buffer (pH 7.6). After incubation in 1:100 goat serum for
20 min at room temperature, they were placed in 1% bovine
serum albumin (BSA) and 1:100 monoclonal cyclin DI
antibody (Novocastra, Newcastle, England) overnight at room
temperature. After two washes with TRIS buffer they were
incubated in 1: 100 biotinylated goat anti-mouse/rabbit
IG(Dako, Glostrop, Denmark) for 30 min, washed subse-
quently twice with TRIS, incubated in 1:100 solution of
streptavidin-biotin complex for 30 min at room temperature,
rewashed in TRIS buffer and placed in diaminobenzene
(10 mg 10ml-') for 10 min, counterstained with haematox-
ylin, washed in water, cleared, dehydrated and mounted. Cyclin
Dl staining was examined according to the intensity of the
majority of cells. The slides were assessed blind, and the
pathologists did not know the results ofthe molecular analyses.
Positive and negative controls were performed for each tumour
series. Two categories of staining were used: nil-weak, and
moderate -strong. A tumour wasconsidered positive in the case
ofa moderate -strong staining. In some cases ofnegative cyclin
DI tumour staining we repeated the analyses in several regions
of the tumour.
Cyclin Dl expression analysis by immunostaining
Tumour sections from the 53 patients were stained using a
cyclin Dl monoclonal antibody. Following the protocol
kindly provided by C Gillett and D Barnes (Gillett et al.,
1994) we found cyclin DI overexpression in 6 out of 14
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Figure 1 (a) Southern blot: Tumour (T) and adjacent normal
lung tissue DNA blot hybridised with the CCNDI and adenosine
deaminase (control) probes. The lanes were loaded with a total of
5jug of Taql-digested DNA. All tumours demonstrate a 3-to 20-
fold increase in CCNDJ copy number compared with adjacent
non-tumour tissue. (b) PCR multiplex analyses: PCR amplifica-
tion of CCNDI and progesterone receptor gene (chromosome
I1q23) showed increase of CCNDI copy number compared with
control genes, confirming the Southern analysis and excluding an
aberrant copy number of chromosome 11.Cyclin Dl in non-small-cell lung cancer
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breast tumours, which was mainly confined to the nucleus. In
our 53 lung tumours moderate-strong staining occurred at a
similar overall frequency (25/53, 47%). All tumours with
amplification of the CCNDJ gene demonstrated overexpres-
sion of cyclin Dl. Additionally, 17 tumours (32%) with an
apparently normal gene copy number also showed increased
cyclin Dl protein levels. However, in contrast to breast
tumours, the cyclin DI intracellular distribution varied.
Simultaneous nuclear and cytoplasmic staining was observed
in 7/53 (13%) cases, and specific cytoplasmic or nuclear
staining was seen in 15/53 (28%) and 3/53 (6%) cases
respectively (Figure 2). Tumours with CCNDI amplification
showed nuclear (n =3), cytoplasmic (n=3) or both, nuclear
and cytoplasmic staining (n =2). In order to exclude a
fixation artifact we assessed the cyclin Dl overexpression in
33 NSCLC tumours fixed in the Wythenshawe Hospital. A
very similar result (nuclear staining 2/33, cytoplasmic 6/33
and nuclear and cytoplasmic 3/33) was obtained in those
patients, rendering this explanation rather unlikely. The cause
and significance of this altered subcellular localisation,
however, is not clear and cyclin Dl expression was further
investigated using RT-PCR.
Allele-specific cyclin DI expression
A polymorphism of cyclin DI located in the 3' untranslated
region allows a PCR-based determination of allele-specific
expression within RNA samples by RFLP analysis (Heigh-
way, 1991). Twenty-nine out of the 53 tumour samples were
informative for this polymorphism. All informative patients
with cyclin Dl overexpression (n = 14) had an imbalance in
allele-specific expression levels suggesting up-regulation of
one parental gene, consistent with the immunostaining results
(Figure 3). However, in the case of the three tumours with
both CCNDI amplification and cytoplasmic cyclin Dl
staining, the allele imbalance was present but paradoxically,
the amplified allele appeared to show reduced expression
relative to the unamplified allele. As it is reasonable to
assume that the amplified allele is in fact overexpressed, these
results suggest that the majority of CCNDI mRNA encoded
from this allele may be spliced in a way precluding PCR
amplification of the cDNA with the primers necessary to
visualise the RFLP.
Association of histopathologicalfindings and clinical outcome
Tumours with cyclin Dl overexpression were less differ-
entiated (P=0.04) and showed less lymphocytic infiltration
(P=0.02). There was no difference in stage and tumour size
at time of surgery. Sex, age distribution and histological type
of tumour had no influence on cyclin Dl expression (Table
I). Overall survival did not differ significantly in the two
groups (P=0.5). Similarly EFS did not differ significantly
(P=0.26). However, examination of the type-specific event
rates (Figure 4) revealed a significantly increased risk of local
relapse in the cyclin DI-negative group (P=0.01), with very
similar rates of metastases alone and a decreased death rate
from other causes, although not significantly (P=0.09). The
increased risk of local relapse was maintained after
adjustment for age, T-stage, N-stage and tumour differentia-
tion (P=0.01, Table II). The estimated relative risk of local
relapse was 9.1 in the cyclin DI-negative groups compared
with the positive group with approximately 95% CI
(1.5,55.4).
Discussion
GI cyclins such as cyclin Dl and their cyclin-dependent
kinases (CDKs) are proving to be integrators of growth
factor-mediated signals driving cells through the restriction
point (START), early in the G, phase of the cell cycle (Pines,
1993; Sherr, 1993, 1994). Growth factors act by binding to
specific cell-surface receptors, which in turn trigger signalling
cascades that ultimately govern the transcription of genes
important in cell growth. The cyclin Dl gene, CCNDJ, was
originally identified as the proto-oncogene (PRADI), clonally
rearranged with the parathyroid hormone gene, in parathyr-
oid adenomas (Motokura et al., 1991). Its ability to rescue GI
cyclin-defective yeast (Lew et al., 1991; Xiong et al., 1991)
suggested that this protein was a cell-cycle regulator. In
addition, the murine homologue ofcyclin Dl, CYLI, isolated
from mouse macrophages was induced by colony-stimulating
factor 1 (CSF-1) (Matsushime et al., 1991). In human cell
lines, cyclin Dl is stimulated by mitogens during G,, and,
upon persistent growth factor stimulation, it is continuously
synthesised throughout the cell cycle (Sewing et al., 1993).
However, it executes its critical function during mid-to-late
G, phase, as cells cross the first cell cycle restrction point (for
review see Motokura and Arnold, 1993b; Hunter and Pines,
1994; Sherr, 1995).
Several lines of evidence suggest that cyclin Dl might play
a crucial role in carcinogenesis. Firstly, in addition to its
involvement in parathyroid adenomas, in centrocytic B cell
lymphomas (mantle cell lymphomas) CCNDI expression is
up-regulated under the influence of the immunoglobulin
heavy-chain gene enhancer, as a result of a reciprocal
chromosomal translocation at the BCLI breakpoint,
t(ll;14)(qI3;q32) (Withers et al., 1991; Seto et al., 1992; de
Boer et al., 1993). Overexpression of cyclin Dl has been
demonstrated in almost all lymphoproliferative disorders
carrying this translocation (Bosch et al., 1994; Lukas et al.,
1994; de Boer et al., 1995; Delmer et al., 1995). Secondly, the
CCNDI gene has been shown to be frequently amplified and
overexpressed in many tumours, such as breast (Lammie et
al., 1991; Schuuring et al., 1992; Gillett et al., 1994), head and
neck (Williams et al., 1993; Callender et al., 1994; Muiller et
al., 1994), laryngeal (Jares et al., 1994), oesophageal ( Jiang et
al., 1992; Jiang et al., 1993; Kanda et al., 1994; Ad6laide et
al., 1995), hepatocellular (Zhang et al., 1993; Nishida et al.,
1994) and lung (Shapiro et al., 1995) carcinomas.
The role of cyclin DI in carcinogensis has been
strengthened by in vitro studies demonstrating its oncogenic
potential. Constitutive overexpression in rodent cells can
shorten G, phase (Quelle et al., 1993). Similarly, in breast
cancer cells arrested in G1, cyclin Dl induction is sufficient to
complete a cell cycle and shortens GI/S phase (Musgrove et
al., 1994). Conversely, microinjection of cyclin Dl antibodies
or antisense plasmid into dividing cells blocks them in the GI
phase (Baldin et al., 1993; Quelle et al., 1993). Transfection of
CCNDI expression constructs into normal fibroblasts
stimulates proliferation by reduction of the G,/S (Quelle et
al., 1993). Consistent with this, by complementing a defective
adenovirus ElA oncogene, cyclin Dl can immortalise cells
(Hinds et al., 1994), and finally when transfected into normal
fibroblasts with activated HRAS, it promotes the formation of
fibrosarcomas in nude mice (Lovec et al., 1994). In conclusion,
there is no doubt that cyclin Dl may act as an oncogene.
The mechanism of action of cyclin Dl is not fully
established and is still a field of intensive research. Never-
theless, one clue to its function comes from the fact that the
retinoblastoma protein (pRb) is down-regulated in an
undulating fashion in late GI (Wiman, 1993), and that the
pRb inactivation (permitting cell proliferation) occurs
predominantly by phosphorylation of its threonine and
serine residues. Interactions between cyclin Dl and other
cell-cycle regulators, such as cyclin-dependent kinases
(CDK4, CDK6) and the interaction of cyclin DI/CDK4
complexes with p16 (CDK4) have recently been suggested to
play an important role in lung tumorigenesis (Shapiro et al.,
1995). There are now accumulating data, showing MTSJ (the
gene encoding p16) missense mutations and deletions with
probable consequent loss of p16 function in some tumour
types. In oesophageal carcinomas the mutation rate was 21-
50% (Mori et al., 1994; Zhou et al., 1994), in head and neck
carcinomas 10% (Zhang et al., 1994) and in NSCLC 10-
30% (Hayashi et al., 1994). In several lung cancer cell lines
and tumour specimens, the presence of p16 protein is
inversely correlated with detectable pRb and cyclin Dl
proteins (Serrano et al., 1993; Shapiro et al., 1995). InCyclin Dl in non-small-cell lung cancer
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Figure 3 RFLP analysis of CCND1 PCR products from three
patients. Normal lung DNA from patient (N) (lanes 1 and 4),
NSCLC DNA (T) (lanes 2, 5, 7) and cDNA (T*) (lanes 3, 6, 8):
Lanes 1 -3, 4-6, the amplified allele is overexpressed (both
tumours showed nuclear cyclin Dl staining), lanes 7-8, tumour
DNA shows no allelic imbalance but transcript levels are clearly
imbalanced (cytoplasmic cyclin Dl overexpression); lane 9,
phiX174 HaeIII marker (Promega).
Table I Association of cyclin Dl overexpression and patient
characteristics
Cyclin Dl not Cyclin Dl
overexpressedoverexpressed P-value
Number of patients 28 25
Sex P=0.15
Male 24 25
Female 4 0
Age (years) P=0.94
Range 48-78 45-79
Median 63.5 65
Mean+SD 64.1+7.1 63.3±9.0
Histology P=0.99
Squamous carcinoma 19 16 (squamous vs
Adenocarcinoma 4 7 others)
Large cell 0 2
Carcinoid 1 0
NSCLC 4 0
Stage P=0.33
1 18 11
2 2 3
3 8 11
Surgical intervention P=0.73
Lobectomy 19 19
Pneumonectomy 9 6
Tumour size (cm) P= 0.68
Range 1-9.3 2-8.6
Median 4.0 4.0
Mean±SD 4.3+2.1 4.4± 1.7
missing values 3 1
Tumour differentiation P=0.04
Good 10 2
Intermediate-poor 18 23
Lymphocytic infiltration of
the tumour P=0.02
Poor 10 18
Moderate to important 18 7
Figure 2 Cyclin Dl immunostaining of NSCLC with mono-
clonal antibody (Novocastra, Newcastle, UK). (a) Nuclear
staining. (b) Cytoplasmic staining. (c) Simultaneous nuclear and
cytoplasmic staining.
particular, cells lacking functional pRb have no cyclin Dl/
CDK4 complexes (Bates et al., 1994), and in NSCLC cell
lines, p16 was absent when pRb function was normal and
present when pRb was mutated (Otterson et al., 1994). These
results highlight the importance of the cyclin Dl-CDK4-
p16 pathway in tumorigenesis.
A monoclonal cyclin Dl antibody allows the detection of
cyclin Dl by immunohistochemistry, enabling a clear
distinction to be made between different levels of expres-
sion. Gillet et al. (1994) have found an excellent correlation
between CCNDI gene amplification and cyclin Dl over-
expression with this antibody. Immunostaining of sections
from the eight lung tumours with CCNDI amplification
showed that all overexpressed the protein. High-level
expression was also seen in a further 17 cases in which
amplification of the gene could not be demonstrated. In
contrast to previous studies on other malignancies (Jiang et
al., 1993; Zhang et al., 1993; Bartkova et al., 1994, 1995;
Gillett et al., 1994)) in which cyclin Dl was confined to the
nucleus, in our study, cyclin DI protein was frequently
observed at high levels, and sometimes exclusively, within the
cytoplasm of the tumour cells. This finding is in agreement
with the very recently published report (Lukas et al., 1995) on
cyclin Dl and D2 in in vitro growing U-2-OS cells showing
subcellular cytoplasmic localisation, during the G,/S phase
while nuclear was observed during the GI phase. The authors
suggest a possible change of solubility of the protein
dependent on the cell-cycle phase. Others have also reported
cytoplasmic or cytoplasmic+nuclear cyclin Dl staining in
mantle cell lymphoma (Banno et al., 1994; Nakamura et al.,
1994). Different contrasting functions (positive regulators of
growth in combination with CDK4 and CDK6, but an
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Figure 4 Cumulative risk of first event ( ), which is the sum
of local relapse (- - -), distant metastases only (- -), and death
from other causes (- -). Patients whose tumours were cyclin DI
negative, (n = 28) (a) or positive (n =25) (b) are shown. There is an
increased risk of local relapse in the cyclin DI-negative group
(P=0.01).
inhibitor of CDK2) have been reported recently and might
explain why some functional experiments have produced
paradoxical results (Peters, 1994). In particular, cyclin Dl
overexpression may lead in post-mitotic neurons to apoptosis
(Freeman et al., 1994), and in human diploid fibroblasts it
might induce senescence (Dulic et al., 1993; Lucibello et al.,
1993).
Allele-specific expression analysis was carried out in the
tumours studied. In all RFLP informative cases, in which
elevated protein levels were demonstrated, an imbalance in
allele-specific relative transcript abundance was seen. Con-
versely, no tumours scoring negative for cyclin D1 expression
by immunostaining displayed an imbalance in transcript
Table II Value of five variables in predicting local relapse in 53
patients with NSCLC according to COX regression analysis
Relative
Factor Variable Estimate s.e. risk P-value
Cyclin Dl 0 Positive
1 Negative 2.212 0.901 9.1 0.01
Age (years) 0-< 65
1->,65 -0.489 0.742 0.6 0.50
Stage 0 1-2
1 3 1.234 1.536 3.4 0.41
Lymph node 0 No
metastases I Yes -0.047 1.550 1.0 0.98
Differentiation I Moderate
(reference=well) 0 Others 0.556 0.921 1.7
1 Poor 0.05
0 Others 1.796 0.838 6.0
levels (except for one tumour with a loss of heterozygosity at
the CCNDI locus). These data suggest that overexpression of
CCNDI was caused by specific genetic events affecting just
one parental allele. Thus, the elevated expression seen in the
tumour is not simply a result of non-specific up-regulation of
a gene involved in rapid cell growth but is the result of
genetic alterations directly affecting CCNDJ. In several cases
the transcript imbalance seen in cDNA favoured the non-
amplified allele. As the polymorphic restriction site is located
distant to the coding sequence, within the long 3'UTR, the
most likely explanation for this finding is that the mRNA
encoded by the amplified allele is preferentially spliced,
precluding amplification of the RFLP site.
The results show an association between cyclin DI
overexpression in the primary tumour and a low degree of
differentiation, little lymphocytic infiltration of the tumour,
and a low incidence of local relapse. Consistent with this
result, overexpression of other oncogene products such as the
BCL2 protein (Pezzella et al., 1993), which is known to
inhibit programmed cell death and the epidermal growth
factor receptor (EGFR) (Lee et al., 1989) that mediates the
effects of the EGF and transforming growth factor (TGF)-x
have been associated with a better patient survival. However,
because of the relatively small number of patients in this
study, the confidence interval for the local relapse hazard
ratio was wide, indicating that these data must be interpreted
with caution and require larger studies to confirm the
usefulness of cyclin Dl overexpression as a prognostic factor.
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